Research at Pharmablock Sciences (Nanjing) Inc. has led to the development of spirooxindole compounds acting as 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors and thus reported to be useful for the treatment of viral infections.
Heterobicyclic derivatives characterized as tyrosine-protein kinase ITK/TSK (EMT) inhibitors have been revealed in an Almirall SA patent. They are reported to be useful for the treatment of atopic dermatitis, psoriasis, T-cell lymphoma, alopecia areata and vitiligo.
Genequantum Healthcare Co. Ltd. and Inxmed Co. Ltd. have signed a collaboration agreement under which Genequantum has granted nonexclusive licensing of its proprietary conjugation technology to Inxmed, supporting the development of the next generation of targeted antibody-drug conjugates (ADCs).
Recent studies reported the design of a new generation of phage-based particles for targeted systemic gene delivery, which consist of the packaging of a recombinant rAAV2 DNA by coat proteins of a filamentous phage.
Eleven Therapeutics Ltd. has established a research collaboration with Novo Nordisk A/S for the identification of novel molecules that promote precise delivery of nucleic acid for cardiometabolic diseases by leveraging Eleven’s innovative Deliveri platform.
Writing in The Journal of Enzyme Inhibition and Medicinal Chemistry, researchers from Nantong First People’s Hospital and collaborators recently conducted a study to discover Hsp90 inhibitors with high efficacy and broad antitumor activity.
Cumulus Oncology Ltd. and Leadxpro AG have signed a research collaboration focused on the discovery and development of small molecules targeting an undisclosed and novel cancer-focused G protein-coupled receptor (GPCR).
Researchers from Peking University (PKU) recently presented the discovery and preclinical evaluation of a novel small-molecule inhibitor of pan-αv integrin, C19-9-21, being developed for the treatment of prostate cancer.
RSS
